神经肽Y与慢性肾脏病进展:一项队列研究
该研究在两个欧洲CKD队列(分别随访753例36个月和576例57个月)中分析循环NPY与eGFR、蛋白尿进展及复合肾脏终点(>30% eGFR下降、透析/移植)的关系。结果显示NPY与eGFR下降和蛋白尿增加相关,并独立预测肾脏终点(SHR 1.09,95%CI 1.03-1.16,P=0.005)。
要点
- 循环NPY水平与eGFR下降和蛋白尿增加独立相关。
- NPY可预测复合肾脏终点(>30% eGFR下降、透析/移植)。
- 交感神经系统或NPY分子本身可能参与CKD进展。
核心结论
- NPY与蛋白尿及更快的CKD进展相关,并与更高的肾衰竭风险相关。
- 交感系统和/或NPY分子内在特性可能在CKD进展中发挥作用。
研究设计与样本
- 研究为队列研究,纳入两个欧洲CKD队列,分别随访753例36个月和576例57个月。
- 采用混合线性模型分析NPY与eGFR及蛋白尿随时间变化的关系。
- 采用Fine和Gray模型(考虑死亡竞争风险)分析NPY与复合肾脏终点的关系。
主要发现
- 第一队列平均血浆NPY为104 ± 32 pmol/L,第二队列为119 ± 41 pmol/L。
- 调整分析中,NPY与eGFR进展相关:第一队列-3.60 mL/min/1.73 m2(95%CI -4.46至-2.74,P<0.001),第二队列-0.83 mL/min/1.73 m2(95%CI -1.41至-0.25,P=0.005)。
- 调整分析中,NPY与蛋白尿进展相关:第一队列0.18 g/24 h(95%CI 0.11-0.25,P<0.001),第二队列0.07 g/24 h(95%CI 0.005-0.14,P=0.033)。
- 两队列合并分析中,NPY预测肾脏终点(SHR 1.09,95%CI 1.03-1.16,P=0.005)。
- 第一队列SHR为1.14(95%CI 1.04-1.25),第二队列为1.06(95%CI 0.98-1.15),两者无差异(P=0.25)。
临床怎么用
- 循环NPY可能作为CKD进展和肾衰竭风险的生物标志物,但需进一步验证。
- 针对交感神经系统或NPY通路的干预是否延缓CKD进展尚需研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neuropeptide Y (NPY) is a sympathetic neurotransmitter that has been implicated in various disorders including obesity, gastrointestinal and cardiovascular diseases. METHODS: We investigated the relationship between circulating NPY and the progression of the glomerular filtration rate (GFR) and proteinuria and the risk for a combined renal endpoint (>30% GFR loss, dialysis/transplantation) in two European chronic kidney disease (CKD) cohorts including follow-up of 753 and 576 patients for 36 and 57 months, respectively. RESULTS: Average plasma NPY was 104 ± 32 pmol/L in the first CKD cohort and 119 ± 41 pmol/L in the second one. In separate analyses of the two cohorts, NPY associated with the progression of the estimated GFR (eGFR) and proteinuria over time in both unadjusted and adjusted {eGFR: -3.60 mL/min/1.73 m2 [95% confidence interval (CI): -4.46 to - 2.74] P < 0.001 and -0.83 mL/min/1.73 m2 (-1.41 to - 0.25, P = 0.005); proteinuria: 0.18 g/24 h (0.11-0.25) P < 0.001 and 0.07 g/24 h (0.005-0.14) P = 0.033} analyses by the mixed linear model. Accordingly, in a combined analysis of the two cohorts accounting for the competitive risk of death (Fine and Gray model), NPY predicted (P = 0.005) the renal endpoint [sub-distribution hazard ratio (SHR): 1.09; 95% CI: 1.03-1.16; P = 0.005] and the SHR in the first cohort (1.14, 95% CI: 1.04-1.25) did not differ (P = 0.25) from that in the second cohort (1.06, 95% CI: 0.98-1.15). CONCLUSIONS: NPY associates with proteinuria and faster CKD progression as well as with a higher risk of kidney failure. These findings suggest that the sympathetic system and/or properties intrinsic to the NPY molecule may play a role in CKD progression.
引用
- Zoccali C, D'Arrigo G, Leonardis D, et al. Neuropeptide Y and chronic kidney disease progression: a cohort study. Nephrol Dial Transplant. 2018. PMID: 29370406. doi:10.1093/ndt/gfx351
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。